The California BOP has not offered any scientific or safety-based explanation for why this widely used and celebrated treatment should be restricted
That structural feature is significant: proline residues resist proteolytic cleavage, making the peptide unusually stable in gastric conditions relative to most short peptides [1]
Products offered are primarily intended for research purposes and may not be listed on the Toxic Substances Control Act (TSCA) inventory unless otherwise stated
However, the most important advantage is the very safe profile of BPC (the lethal dose (LD1) could be not achieved) ( in situ hybridization and immunostaining for BPC 157 in the human gastrointestinal mucosa, lung bronchial epithelium, the epidermal layer of the skin, and kidney glomeruli) (Xu et al., 2020)
It does not cause gastrointestinal symptoms
The reconstituted product should be visually transparent and colourless with no suspended particulate